Inovio Pharmaceuticals, Inc. · NASDAQ:INO
Inovio Pharmaceuticals — Q2 2025 Earnings Presentation
21 slides from Inovio Pharmaceuticals's earnings presentation, Aug 12, 2025
Slide 1: Second Quarter 2025 Financial Results
Second Quarter 2025 Financial Results August 2025
Slide 2: Agenda
Agenda Introduction Jennie Willson, Director, Communications CEO Perspective & Corporate Progress Jacqueline Shea, PhD, President & Chief Executive Officer INO-3107 Update Michael Sumner, MBBS, MBA, Chief Medical Officer Steve Egge, MBA, Chief Commercial Officer Financial Results Peter Kies, Chief F
Slide 3: Forward-Looking Statements
Forward-Looking Statements This presentation includes statements that are, or may be deemed, “forward-looking statements,” within the meaning of Section 27A of the Securities Act of 1933, as amended. All statements, other than statements of historical facts, included in this presentation regarding o
Slide 4: Recent Progress on 2025 Strategic Priorities
Recent Submit BLA for INO-3107 Progress • On track to submit BLA in second half of 2025 on 2025 - Completed device design verification (DV) testing required for IND update and BLA submission Strategic - Requested rolling submission from FDA in July 2025 - Long-term efficacy data published in The Lar
Slide 5: INO-3107 for Recurrent Respiratory Papillomatosis (RRP)
LEAD CANDIDATE: INO-3107 for Recurrent Respiratory Papillomatosis (RRP) Potentially transformational therapy under accelerated approval pathway
Slide 6: 2025 Progress Toward BLA Goal
INO-3107 DELIVERING THERAPEUTIC INNOVATION TO PATIENTS 2025 Progress Toward BLA Goal Regulatory • Completed DV testing for device • Requested rolling submission of BLA in July 2025 Timelines • Submit BLA in 2H25 on Track • Goal: receive acceptance of file for review by FDA by year-end Confirmatory •
Slide 7: Reduction in Surgeries Continued to Improve After Year 1
INO-3107 Reduction in Surgeries Continued to Improve After Year 1 ORR was 72% at Week 52, improving to 86% by Week 104 for second twelve-month period The pre-treatment mean for surgeries in the year prior to start of INO-3107 was 4.1 (range 2-8) INO-3107 CLINICAL EFFECT OVER TIME SURGERIES ORR: 72%
Slide 8: Over 75% Fewer Surgeries 2 Years After Initial Treatment Regimen
INO-3107 Over 75% Fewer Surgeries 2 Years After Initial Treatment Regimen MEAN SURGERIES PER YEAR PRE-TREATMENT WeekYEAR -52 to-10(N=32) (N=32) 4.1 WeekYEAR 1 (N=32) 52 Visit (N=32) 1.7 Longer-term therapy could offer POST-TREATMENT YEAR104 Week 2 (N=28) (N=28) 0.9 potential for maintenance and exte
Slide 9: Foundational Strengths of RRP Program
INO-3107 Foundational Strengths of RRP Program Designed with every surgery—and every patient—in mind Unmet • Debilitating rare disease caused primarily by HPV-6 & HPV-11, characterized by small, Medical Need wart-like growths in respiratory tract • Current standard of care (repeat surgeries) does no
Slide 10: RRP Represents a Significant Market Opportunity
INO-3107 RRP Represents a Significant Market Opportunity Disease-modifying therapeutic option 14,000 patients in the U.S., 1.8 per No regulatory-approved 100,000 new cases annually; therapeutic currently available similar estimates in Europe HPV vaccination unlikely Surgical standard of care has to
Slide 11: Market Research Continues to Support Preferred Product Profile
INO-3107 Market Research Continues to Support Preferred Product Profile EFFICACY TOLERABILITY SIMPLICITY Improving response over time Well tolerated Patient-centric treatment • Overall Response Rate (50% to • 41% (13/32) reported treatment- • Office-based administration that 100% reduction in surger
Slide 12: Advancing Launch Preparations
INO-3107 Advancing Launch Preparations • Developed distribution/channel strategy and identified channel partners (3PL, specialty pharmacy, specialty distributor) • Identified a HUB (patient services) partner • Developed initial pricing strategy • Completed targeting, segmentation and product 300-400
Slide 13: 2Q25 Financial Update
2Q25 Financial Update
Slide 14: Making Progress on Strategic Goals While Reducing Costs
Making Progress on Strategic Goals While Reducing Costs THREE MONTHS SIX MONTHS ENDED JUNE 30, 2025 (UNAUDITED) ENDED JUNE 30, 2024 (UNAUDITED) % % 2025 2024 CHANGE 2025 2024 CHANGE Operating expenses $23.1 $33.3 (31%) $48.2 $64.8 (26%) Net loss ($23.5) ($32.2) (27%) ($43.2) ($62.7) (31%) Net loss p
Slide 15: Pipeline Update
Pipeline Update
Slide 16: INOVIO Pipeline
INOVIO Pipeline PRECLINICAL PHASE 1 PHASE 2 PHASE 3 REGISTRATION DMAbs INO-5401 VGX-3100 INO-3107 * Various Targets BRCA 1/2 Mutation Anal Dysplasia RRP DPROTs INO-4201 INO-3112 Various targets Ebola Booster Head & Neck Cancer DLNPs INO-6172 INO-5401 Various targets HIV Glioblastoma INO-6160 HIV DMA
Slide 17: Q&A
Q&A
Slide 18: Anticipated Outreach at Key Scientific Conferences in 2H25
INO-3107 Anticipated Outreach at Key Scientific Conferences in 2H25 • American Academy of Otolaryngology OCTOBER 10-13 • World Vaccine Congress Europe OCTOBER 13-16 • European Society for Medical Oncology OCTOBER 17-21 • 37th International Papillomavirus Society Conference OCTOBER 23-26 • World Orph
Slide 19: Upcoming Key Catalysts
Upcoming Key Catalysts Commercialization Submit BLA for INO-3107 Preparations Progress Pipeline • Begin submitting modules • Be ready to launch quickly DMAb on a rolling basis in 2H25 and efficiently if approved • Complete Phase 1 trial • Continue to build on • Present/publish data • Submit revised
Slide 20: Why each day—and each surgery—matters to RRP patients
Why each day—and each surgery—matters to RRP patients: “ RRP patients will tell you that even one reduction in the number of disruptive, invasive surgeries they face would be life-changing.” Kim McClellan President, RRP Foundation 20
Slide 21: Contact
Contact: investor.relations@inovio.com
INOVIO Pharmaceuticals — Q2 2025 Earnings Presentation on 6ix